CHU Sart-Tilman

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials
• Prostate cancer2 trials
• Bladder cancer1 trial
• Head and neck cancer1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Multiple sclerosis1 trial
• Ovarian cancer1 trial
• Pancreatic cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 33 trials
• Phase 1/22 trials
• Phase 22 trials

Status

• Completed4 trials
• Recruiting2 trials
• Active, not recruiting1 trial
• Terminated1 trial

Lead sponsor

• Hoffmann-La Roche2 trials
• Daiichi Sankyo1 trial
• Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.1 trial
• Inhatarget Therapeutics1 trial
• Janssen Research & Development, LLC1 trial
• and 2 more

Running trials

• Active, not recruiting

  Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)

  NCT05797740· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Recruiting

  Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

  NCT05985655· Phase 1/2· Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.· Source

  Contact: Laurence Lousberg (principal investigator)

• Recruiting

  Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

  NCT06896890· Phase 1/2· Inhatarget Therapeutics· Source

  Contact: A. Sibille, MD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Head and neck cancer1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

  NCT04172675· Phase 2· Janssen Research & Development, LLC· Source

• Terminated

  A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

  NCT03248492· Phase 2· Daiichi Sankyo· Source

• Completed

  Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  NCT03072238· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· pharmaand GmbH· Source

• Completed

  A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

  NCT02908672· Phase 3· Hoffmann-La Roche· Source